Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOARGYS vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Dysmenorrhea,Management of acute pain
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
100 mg orally twice daily.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2C9; formation of inactive metabolites, with less than 1% excreted unchanged in urine.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
85-90% (primarily albumin).
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
0.5-0.7 L/kg (indicates moderate tissue distribution).
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral: 60-70% (first-pass metabolism).
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
GFR 30-59 m L/min: 75 mg twice daily; GFR 15-29 m L/min: 50 mg twice daily; GFR <15 m L/min: not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: not recommended.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Not established; safety and efficacy not studied in patients <18 years.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
No specific dose adjustment required; monitor renal function and adjust based on GFR.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Cardiovascular thrombotic events: NSAIDs, including LOARGYS, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. The risk is higher in patients with cardiovascular disease or risk factors. LOARGYS is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Cardiovascular thrombotic events,Gastrointestinal adverse events (bleeding, ulceration, perforation),Hypertension and exacerbation of hypertension,Renal effects: renal papillary necrosis, interstitial nephritis, and acute renal failure,Hepatic effects: elevations of liver enzymes, severe hepatic reactions,Anaphylactic reactions,Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,Fluid retention and edema,Masking of inflammation and fever
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Hypersensitivity to LOARGYS or any component of the formulation,History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs,Patients with active gastrointestinal bleeding, peptic ulcer disease, or perforation,Advanced renal disease,Treatment of perioperative pain in the setting of CABG surgery,Patients with severe heart failure (NYHA Class IV)
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if taking with potassium-sparing diuretics or in renal impairment. Grapefruit juice may alter drug metabolism; limit intake.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Avoid use during pregnancy due to teratogenicity; no dose adjustment guidelines exist as drug is contraindicated.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
LOARGYS is an angiotensin II receptor blocker (ARB) indicated for hypertension. Avoid in pregnancy (Pregnancy Category D). Monitor serum potassium and renal function periodically. May cause dizziness; advise caution with driving. Combination with NSAIDs may reduce antihypertensive effect and increase renal risk.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by doctor.,Do not stop taking without consulting your doctor.,Report symptoms like lightheadedness, fainting, or swelling.,Use effective contraception during treatment; not safe in pregnancy.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOARGYS vs DESOGEN, answered by our medical review team.
LOARGYS is a Combination Oral Contraceptive that works by LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOARGYS and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOARGYS is: 100 mg orally twice daily.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOARGYS and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOARGYS is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.